Recently, Loxo Oncology, a research and development group of Eli Lilly, and Kumquat Biosciences (Kumquat) announced that the two parties have reached an exclusive collaboration agreement to jointly discover, develop and commercialize a series of innovative small molecule drug candidates that cause tumor-specific immune responses.
As a collaborative partner of Kumquat, Shanghai Medicilon Inc. (Medicilon) congratulates the Kumquat Biosciences on the new progress of small molecule immuno-oncology (IO) platform.
According to the agreement, Kumquat will use its small molecule immuno-oncology (IO) platform to discover the innovative clinical drug candidates, from which Eli Lilly could select a certain number of drug candidates for further development and commercialization of global market except Greater China Region. Kumquat reserves the right to develop and commercialize each drug candidate selected by Eli Lilly in the Greater China region, however Eli Lilly has the right to participate in the joint commercialization of these drugs in the Greater China region. In addition, Kumquat could choose to jointly develop and commercialize certain drug candidates selected by Eli Lilly in the United States.
The collaboration between the two parties is the starting point after Kumquat has focused on small-molecule tumor immunotherapy. As a collaborative partner, Medicilon has the honor to witness the growth of Kumquat. Currently, Medicilon has over 50 researchers providing chemical FTE services for Kumquat. Medicilon is continuing to empower Kumquat with the flexibly adjustable solutions, controllable project progress, and customizable synthesis lines.
Guided by customer needs with the mission of innovative drug research, the FTE team of Medicilon is committed to providing high-quality emerging compounds for new drug research and development organizations. The pharmaceutical service includes medicinal chemistry, compound library design and synthesis, synthetic chemistry and synthetic process research and development. This collaboration model is cost effective and could be flexibly adjusted based on customer and project needs.
“Congratulations to Kumquat and Eli Lilly for reaching collaboration,” Medicilon Founder & CEO Dr. Chunlin Chen said, “Medicilon wishes Kumquat shine in the field of tumor immunotherapy, achieve more innovative research and development results, and bring hope to the tumor patients around the world.”
Kumquat’s mission is to develop innovative therapies to bring about sustainable and life-changing benefits to cancer patients. At Kumquat, we focus on translating breakthrough science to first-in-class therapeutics. Kumquat brings together an accomplished team and distinguished scientific founder with a proven track record of innovative oncology drug discovery and development.
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. Medicilon grows together with the clients and delivers the new drug research and development services to more than 900 clients globally. Medicilon is proud to contribute to human health in the globe.
Relevant
news
marketing@medicilon.com
